Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Outside of clinical trials, pre-licence access in the UK may theoretically occur via the MHRA's Early Access to Medicines Scheme (EAMS), though no such scheme for retatrutide is publicly available at the time of writing
Gastrointestinal symptoms: Mild nausea is common during the first week at each new dose
Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbol JD, Hansen T, et al
2 trial to assess its ability to attenuate endometriosis-related non-menstrual pelvic pain, expected to readout mid-2027
Individualized Treatment: Semaglutide is not suitable for everyone, and its usage in a weight loss program is based on individual health profiles, medical history, and consultation with healthcare professionals
Depending on the option selected, glutathione is delivered through an IV infusion, IV push, or intramuscular injection under licensed medical supervision
